Applicant, as named in the Orange Book

Cheplapharm

Part of Cheplapharm

Company and ticker: cliffwatch mapping, checked against SEC EDGAR

Next listed expiry: Valcyte on 11 Dec 2027. 1 products with live protection, 10 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Valcyte NDA 022257 valganciclovir hydrochloride	valganciclovir hydrochloride	11 Dec 2027 patent	patent

Recent events

Zyprexa · Generic approved · ANDA 219048, Omnivium PharmsApproved 23 Jan 2026Detected 25 Oct 2026
Valcyte · Generic approved · ANDA 218838, Micro LabsApproved 19 Mar 2026Detected 25 Oct 2026
Zyprexa · Generic approved · ANDA 220323, AdaptisApproved 5 Mar 2026Detected 25 Oct 2026

Products without listed protection (10)

Drug	Ingredient	Earliest generic entry	Basis
Etopophos Preservative Free NDA 020457 etoposide phosphate	etoposide phosphate	open now no listed protection	no listed protection
Klonopin NDA 017533 · 3 strengths clonazepam	clonazepam	open now no listed protection	no listed protection
Pulmicort Flexhaler NDA 021949 · 2 strengths budesonide	budesonide	open now no listed protection	no listed protection
Seroquel NDA 020639 · 6 strengths quetiapine fumarate	quetiapine fumarate	open now no listed protection	no listed protection
Seroquel Xr NDA 022047 · 5 strengths quetiapine fumarate	quetiapine fumarate	open now no listed protection	no listed protection
Xenical NDA 020766 orlistat	orlistat	open now no listed protection	no listed protection
Zyprexa NDA 020592 · 6 strengths olanzapine	olanzapine	open now no listed protection	no listed protection
Zyprexa NDA 021253 olanzapine	olanzapine	open now no listed protection	no listed protection
Zyprexa Relprevv NDA 022173 · 3 strengths olanzapine pamoate	olanzapine pamoate	open now no listed protection	no listed protection
Zyprexa Zydis NDA 021086 · 4 strengths olanzapine	olanzapine	open now no listed protection	no listed protection